Vitreo Retinal Associates
Vitreo Retinal Associates is a private, physician-owned vitreoretinal subspecialty practice in North Florida operating three offices (Gainesville, Lake City, Ocala) with four fellowship-trained surgeons delivering medical, surgical, and clinical trial services for inherited and acquired retinal diseases.
- Company typePrivate
- Founded1998
- HeadquartersGainesville, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Vitreo Retinal Associates does
Vitreo Retinal Associates (VRA), P.A. is a private vitreoretinal subspecialty medical practice founded in 1998 and headquartered in Gainesville, Florida, with two additional offices in Lake City and Ocala. The practice is operated as a Professional Association (P.A.) under physician ownership, with affiliation to EyeSouth Partners, a strategic eye care management company. VRA employs between 11 and 50 staff and is led by four fellowship-trained vitreoretinal surgeons — Dr. Kaushik M. Hazariwala (founding physician since 1998), Dr. Christine Nichols Kay (Director of Clinical Research and partner since 2014), Dr. M. Brandon Parrott (joined 2017), and Dr. Siva Iyer (joined 2016) — who collectively cover inherited retinal disease, complex retinal detachment repair, diabetic eye disease, and age-related macular degeneration.
The practice delivers medical and surgical vitreoretinal care supported by a diagnostic suite that includes Fullfield Ganzfeld and Multifocal electroretinography (Diagnosys Espion), Visual Field testing (Octopus 900), Microperimetry (Nidek MP1-S), Widefield Fluorescein Angiography/Autofluorescence (Optos California), and Spectral Domain OCT (Heidelberg). An active clinical research program, led by Dr. Kay, conducts trials across inherited retinal disease gene therapy (Stargardt, choroideremia, achromatopsia, retinitis pigmentosa, X-linked RPGR), geographic atrophy, wet and dry AMD, and diabetic macular edema with sponsors including Novartis, Spark/Roche, Regenxbio, Adverum, Janssen, 4D Molecular Therapeutics, MeiraGTx, and Alkeus.
VRA generates revenue through three streams: (1) professional services from patient consultations, in-office diagnostic testing and procedures billed at time of service; (2) surgical services performed at the adjacent North Florida Surgical Pavilion; and (3) clinical research program revenue from sponsored trials. Patient acquisition is primarily physician-referral based with supplemental direct scheduling and emergency coverage seven days a week. Pricing is pay-as-you-go with major credit cards accepted (3.5% surcharge on card transactions) and insurance billing; specific fees are not publicly disclosed.
Vitreo Retinal Associates firmographics
Firmographics- Name
- Vitreo Retinal Associates
- Legal name
- Vitreo Retinal Associates, P.A.
- Website
- https://vra-pa.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vitreo Retinal Associates is a private, physician-owned vitreoretinal subspecialty practice in North Florida operating three offices (Gainesville, Lake City, Ocala) with four fellowship-trained surgeons delivering medical, surgical, and clinical trial services for inherited and acquired retinal diseases.
- Ownership category
- akta.pro rank
Vitreo Retinal Associates industry classification
Industry- Product category
- Vitreoretinal Specialty Ophthalmology
- NAICS
- Offices of Physicians (62111)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Retina & Vitreous Specialists (HLAKAKAE)
- akta.pro secondary industries
- Ambulatory Surgery Centers (Ophthalmic/Outpatient Eye Surgery) (HLAKAKAO), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Vitreo Retinal Associates is headquartered
LocationHeadquarters
- HQ city
- Gainesville
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Vitreo Retinal Associates business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Medical Services - Office Visits and Procedures: Revenue generated from patient consultations, diagnostic testing, and in-office procedures for retinal diseases. Payment is due when services are rendered unless prior arrangements have been made.
- Surgical Services: Revenue from retinal and vitreous surgeries performed at the North Florida Surgical Pavilion in Gainesville, including treatments for retinal detachment, diabetic tractional retinal detachment repair, and other surgical interventions.
- Clinical Research: The practice conducts clinical trials for various retinal diseases including gene therapy, allowing patients access to experimental treatments while generating research-related revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Standard medical services - fees vary by procedure and consultation type |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Vitreo Retinal Associates product offering
Product offeringCore offering
Vitreo Retinal Associates is a specialized ophthalmology practice providing medical and surgical treatment of vitreoretinal diseases, including retinal detachment repair, diabetic eye disease management, and age-related macular degeneration care. The practice operates three Florida offices and an advanced diagnostic suite (electrophysiology, OCT, microperimetry, widefield angiography) alongside an active clinical research program conducting gene therapy trials for inherited retinal diseases.
Product overview
Vitreo Retinal Associates is a medical practice offering a unified portfolio of specialized vitreoretinal healthcare services. The core offering consists of medical and surgical treatment for retinal diseases, supported by an advanced diagnostic services suite that includes electrophysiology testing (Fullfield Ganzfeld ERG, Multifocal ERG, Dark Adaptometry, EOG using Diagnosys Espion), visual field assessment (Octopus 900), microperimetry (Nidek MP1-S), widefield angiography (Optos California), and spectral domain OCT (Heidelberg system). The practice also operates an active clinical research program investigating gene therapy and novel treatments for inherited retinal diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Medical and Surgical Vitreoretinal Services Specialized medical and surgical services for the diagnosis and treatment of vitreoretinal diseases, including retinal detachment repair, diabetic eye disease treatment, and age-related macular degeneration management, delivered by fellowship-trained specialists across three Florida offices and at the North Florida Surgical Pavilion.
- Electrophysiology Diagnostic Services Specialized retinal diagnostic testing using the Diagnosys Espion system, including Fullfield Ganzfeld ERG with dark adaptometry and EOG, and Multifocal ERG for Plaquenil screening, providing comprehensive retinal function assessment.
- Visual Field Testing (Octopus 900) Static and kinetic perimetry testing using the Octopus 900 system for comprehensive visual field assessment in retinal disease patients.
- Microperimetry (Nidek MP1-S) Microperimetry testing using the Nidek MP1-S system that correlates macular anatomy to function, assessing the relationship between retinal structure and visual performance.
- Widefield Fluorescein Angiography and Autofluorescence (Optos California) Widefield retinal imaging using the Optos California system for fluorescein angiography and autofluorescence examinations of the retina.
- Spectral Domain OCT (Heidelberg System) High-resolution retinal cross-sectional imaging using spectral domain optical coherence tomography with autofluorescence capability for diagnosing and monitoring retinal diseases.
- Clinical Research Program Active clinical research program led by Dr. Christine Kay as Director of Clinical Research, conducting sponsored clinical trials in inherited retinal disease, gene therapy, age-related macular degeneration, diabetic macular edema, geographic atrophy, and other retinal conditions, in partnership with biopharmaceutical sponsors and the Foundation Fighting Blindness.
Companies that use Vitreo Retinal Associates
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
Vitreo Retinal Associates technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Vitreo Retinal Associates partnerships and signals
Strategic signalPartnerships
29 partnerships are on record, tiered core and minor.
- Opus TherapeuticscoreDr. Christine Kay serves as Chief Ophthalmology Advisor for Opus Therapeutics, a biotechnology company developing treatments for retinal diseases.
- Sparing VisionminorDr. Christine Kay serves on the Data Safety Monitoring Committee for Sparing Vision, a company developing treatments for retinal degeneration.
- NanoscopeminorDr. Christine Kay serves as a consultant for Nanoscope, a company developing optogenetic therapies for retinal diseases.
- Kiora PharmaceuticalsminorDr. Christine Kay serves as a consultant for Kiora Pharmaceuticals, developing treatments for retinal diseases.
- KodiakcoreDr. Christine Kay serves as a consultant for Kodiak, a company developing novel therapeutics for retinal diseases including KSI-301 for wet AMD and DME.
- Ascidian TherapeuticsminorDr. Christine Kay serves as a consultant for Ascidian Therapeutics, a company developing RNA-based therapeutics for ocular diseases.
- Atsena TherapeuticscoreDr. Christine Kay serves as Clinical Ophthalmology Advisor for Atsena Therapeutics, a clinical-stage gene therapy company focused on inherited retinal diseases.
- NovartiscoreDr. Christine Kay serves as a consultant for Novartis, a major pharmaceutical company developing ophthalmic treatments.
- Spark TherapeuticscoreDr. Christine Kay served as Speaker and Consultant for Spark Therapeutics (now part of Roche), which developed voretigene neparvovec (Luxturna) for inherited retinal disease.
- Jaeb Center for Health ResearchcoreClinical research partner for natural history studies including Pro-EYS and RUSH2A studies on retinal degeneration progression.
- National Eye Institute (NEI)coreSponsor of NAC ATTACK clinical trial for N-Acetylcysteine in retinitis pigmentosa patients.
- 4D Molecular TherapeuticscorePartner for 4D-150 gene therapy clinical trials for wet AMD and 4D-125 for X-linked retinitis pigmentosa.
- MeiraGTx UK II Ltd.coreSponsor of AAV5-hRKp.RPGR gene therapy trials for X-linked retinitis pigmentosa (Protocols MGT-RPGR-021 and MGT-RPGR-022).
- Gyroscope/NovartiscoreSponsor of ORACLE long-term follow-up study for GT005 in geographic atrophy secondary to AMD.
- NightstaRx Ltd (Biogen)minorSponsor of SOLSTICE long-term follow-up study for AAV2-REP1 gene therapy for choroideremia.
- Alkeus PharmaceuticalscoreSponsor of SAGA trial and TEASE study for ALK-001 (C20-D3-Vitamin A) in Stargardt disease.
- Applied Genetic Technologies Corp (AGTC)coreSponsor of AAV gene therapy trials for CNGB3 and CNGA3 achromatopsia.
- RegenxbiocoreSponsor of ATMOSPHERE and ASCENT studies for RGX-314 gene therapy in neovascular AMD.
- Belite BiominorSponsor of Phase 3 trial for Tinlarebant (LBS-008) in adolescent Stargardt disease.
- IVERIC biominorSponsor of Zimura trials in Stargardt disease and geographic atrophy.
- EyeBiominorSponsor of EYE103 clinical trial comparing EYE103 to ranibizumab in diabetic macular edema.
- Stealth BioTherapeuticsminorSponsor of ReNEW trial for Elamipretide in dry AMD.
- JanssencoreSponsor of long-term extension study for JNJ-81201887 in geographic atrophy.
- Boehringer IngelheimminorSponsor of JADE trial for BI 1584862 in geographic atrophy.
- AdverumcoreSponsor of ARTEMIS Phase 3 trial for Ixoberogene Soroparvovec (Ixo-vec) in wet AMD.
- OcugencoreSponsor of Phase 1/2/3 trial for OCU410ST for Stargardt disease.
- Stargazer PharmaceuticalsminorSponsor of STG-001 trial in Stargardt disease (STGD1).
- Foundation Fighting BlindnesscoreDr. Christine Kay serves as consultant; practice participates in Foundation Fighting Blindness clinical trials and received Career Development Award totaling $375,000.
- North Florida Surgical PavilioncoreSurgical facility adjacent to North Florida Regional Medical Center where retinal surgeries are performed.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Vitreo Retinal Associates competitors and assessment
Company assessmentDirect peers
- Retina Specialty Institute: Multi-physician vitreoretinal practice with active clinical research program and gene therapy trial participation; directly comparable specialty mix and physician-owned structure.
- Tennessee Retina: Regional vitreoretinal specialty practice where Dr. Parrott previously worked; directly comparable subspecialty focus, clinical research portfolio, and physician-owned private practice model.
- Bascom Palmer Eye Institute: Academic vitreoretinal center where Dr. Parrott trained; operates as the gold-standard retinal referral and research center, drawing the most complex inherited retinal disease cases nationally.
- Retina Consultants of Texas: Large multi-site vitreoretinal specialty group with extensive clinical research program and gene therapy trial participation; comparable subspecialty clinical and research model at greater scale.
- Florida Retina Institute: Multi-physician vitreoretinal specialty practice operating in Florida with similar retinal disease focus, surgical capabilities, and clinical research offerings.
- Retina Associates of Florida: Multi-physician vitreoretinal specialty practice serving Florida with similar surgical and clinical research offerings; directly comparable specialty mix, patient population, and physician-owned P.A. structure.
Regional players
- Miami Retina Center: Vitroretinal specialty practice operating in South Florida; comparable subspecialty focus but serves a different Florida geography, creating indirect regional overlap.
Broad incumbents
- EyeSouth Partners: Strategic acquirer and management company for ophthalmology practices including VRA; comparable because it represents the platform/parent consolidating retina and comprehensive ophthalmology practices across the Southeast.
- Center for Sight (Florida): Large multi-specialty ophthalmology group where Dr. Parrott previously practiced; provides vitreoretinal services as part of broader ophthalmology portfolio, including LASIK/cataract and clinical research.
Others
- Foundation Fighting Blindness: Non-profit funding clinical research in inherited retinal diseases; VRA physicians serve as consultants and participate in FFB-funded trials — adjacent ecosystem enabler for inherited retinal disease research.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Vitreo Retinal Associates social profiles
Digital presenceVitreo Retinal Associates financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitreo Retinal Associates leadership team
Management profileNumber of profiles
Profiles4 records
Vitreo Retinal Associates funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitreo Retinal Associates M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitreo Retinal Associates
What does Vitreo Retinal Associates do?
Vitreo Retinal Associates is a specialized ophthalmology practice providing medical and surgical treatment of vitreoretinal diseases, including retinal detachment repair, diabetic eye disease management, and age-related macular degeneration care. The practice operates three Florida offices and an advanced diagnostic suite (electrophysiology, OCT, microperimetry, widefield angiography) alongside an active clinical research program conducting gene therapy trials for inherited retinal diseases.
Is Vitreo Retinal Associates a public or private company?
Vitreo Retinal Associates is a private company. It is classified as management employee owned and is currently operating.
When was Vitreo Retinal Associates founded?
Vitreo Retinal Associates was founded in 1998. It employs 11 to 50 people.
Where is Vitreo Retinal Associates based?
Vitreo Retinal Associates is headquartered in Gainesville, United States, in the North America region.
How does Vitreo Retinal Associates make money?
Three revenue lines are on record. Medical Services - Office Visits and Procedures are the primary driver. The others are surgical Services and clinical Research.
Who are Vitreo Retinal Associates's main competitors?
Direct peers on record are Retina Specialty Institute, Tennessee Retina, Bascom Palmer Eye Institute, Retina Consultants of Texas, Florida Retina Institute and Retina Associates of Florida. Miami Retina Center is listed as a regional player. Broad incumbents are EyeSouth Partners and Center for Sight (Florida). Foundation Fighting Blindness is listed as an others.
Does Vitreo Retinal Associates have an API?
No public API is recorded for Vitreo Retinal Associates.
What industry is Vitreo Retinal Associates in?
Vitreo Retinal Associates's product category is Vitreoretinal Specialty Ophthalmology. Its primary akta.pro industry code is HLAKAKAE, Retina & Vitreous Specialists, with a secondary code of HLAKAKAO, Ambulatory Surgery Centers (Ophthalmic/Outpatient Eye Surgery). Its NAICS code is 62111 and its SIC code is 8011.